Pharmaceutical stocks often outperform during market downturns because they pay dividends and their products are mostly ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

It's a good time to take a breather, assess the underlying business, and consider whether the stock's decline offers enough value to make AbbVie a buy despite all this noise. If you've followed ...

In this article, you will learn about extra reasons why I continue to cover AbbVie with a 'Strong Buy' rating. The North Chicago-based company's revenue reached $13.34 billion, and its non-GAAP ...